IWC
AVIR icon

Integrated Wealth Concepts’s Atea Pharmaceuticals AVIR Stock Holding History

Integrated Wealth Concepts’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$30.5K – 1649
2023
Q4 		$30.5K Hold
10,000
– – ﹤0.01% 1572
2023
Q3 		$30K Hold
10,000
– – ﹤0.01% 1526
2023
Q2 		$37.4K Sell
10,000
-140
-1% -$524 ﹤0.01% 1526
2023
Q1 		$34K Buy
+10,140
New +$41.1K ﹤0.01% 1315

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Integrated Wealth Concepts's AVIR Position: Q1 2024 in Review

Integrated Wealth Concepts sold out of Atea Pharmaceuticals (AVIR) in Q1 2024, closing a stake of 10,000 shares — an estimated $30.5K sold.

Integrated Wealth Concepts first reported a position in AVIR in Q1 2023 and held it in 4 quarters. The position peaked at $37.4K in Q2 2023. 113 funds tracked by Wall St. Rank hold AVIR as of Q1 2024.

  • Integrated Wealth Concepts reported no remaining Atea Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Integrated Wealth Concepts sold 10,000 Atea Pharmaceuticals shares in Q1 2024, an estimated $30.5K.
  • Integrated Wealth Concepts first reported a position in Atea Pharmaceuticals in Q1 2023 and held it in 4 quarters.
  • Integrated Wealth Concepts's Atea Pharmaceuticals position peaked at $37.4K in Q2 2023.
  • 113 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2024.

Based on Integrated Wealth Concepts's 13F filing for Q1 2024, filed 15 May 2024.